New cocktail of three drugs targets Hard-to-Treat lymphoma
NCT ID NCT06824701
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This early-phase trial is testing whether combining three drugs—tazemetostat, zanubrutinib, and an anti-CD20 antibody (rituximab or obinutuzumab)—is safe and effective for people with certain types of lymphoma that have come back or not responded to treatment. The study involves 24 adults with mantle cell lymphoma, marginal zone lymphoma, Waldenström macroglobulinemia, or follicular lymphoma. The main goal is to find the highest safe dose of tazemetostat when used in this combination.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tazemetostat, zanubrutinib, rituximab or obinutuzumab
- What this could lead to
- If successful, this could point toward a new combination treatment option for people with certain types of lymphoma that have not responded to prior therapies.
- What could go wrong
- This is a very early (Phase 1) and small (24 participants) trial focused on safety and dosing, not yet on effectiveness. The study is currently suspended, and the combination may cause significant side effects or fail to show benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huntsman Cancer Institute at University of Uta
Salt Lake City, Utah, 84112, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted drug boost standard therapy for a rare lymphoma?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Can a targeted drug boost standard chemo for a rare blood cancer?
- Can a second CAR T-Cell infusion beat lymphoma that returns?
- Smartwatches track hidden heart risk in blood cancer patients
- Triple-Drug attack aims to outsmart mantle cell lymphoma